Quanterix Co. (NASDAQ:QTRX) Shares Bought by Millennium Management LLC

Millennium Management LLC lifted its position in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,185,101 shares of the company's stock after purchasing an additional 122,969 shares during the period. Millennium Management LLC owned about 5.67% of Quanterix worth $23,228,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of QTRX. Barclays PLC lifted its position in shares of Quanterix by 42.3% during the 3rd quarter. Barclays PLC now owns 146,248 shares of the company's stock worth $1,896,000 after purchasing an additional 43,447 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Quanterix by 28.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 217,957 shares of the company's stock worth $2,825,000 after purchasing an additional 47,873 shares during the last quarter. Tallon Kerry Patrick purchased a new stake in shares of Quanterix during the 4th quarter worth $169,000. Janney Capital Management LLC lifted its position in shares of Quanterix by 40.9% during the 4th quarter. Janney Capital Management LLC now owns 33,192 shares of the company's stock worth $353,000 after purchasing an additional 9,639 shares during the last quarter. Finally, abrdn plc lifted its position in shares of Quanterix by 24.4% during the 4th quarter. abrdn plc now owns 206,923 shares of the company's stock worth $2,200,000 after purchasing an additional 40,525 shares during the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Stock Performance

NASDAQ QTRX traded up $0.02 during trading on Monday, reaching $4.85. The company's stock had a trading volume of 409,846 shares, compared to its average volume of 573,581. The firm has a market cap of $188.32 million, a price-to-earnings ratio of -4.58 and a beta of 1.12. Quanterix Co. has a twelve month low of $4.05 and a twelve month high of $19.18. The business's fifty day moving average price is $5.60 and its 200-day moving average price is $8.36.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.16. The company had revenue of $30.33 million for the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, sell-side analysts forecast that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Thursday. Canaccord Genuity Group reduced their price target on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Leerink Partnrs cut shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Leerink Partners reissued a "market perform" rating and issued a $8.00 price target (down from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Finally, Scotiabank reissued an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Quanterix currently has an average rating of "Hold" and a consensus target price of $15.60.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.